AmpliMed Announces Two Senior Appointments.TUCSON, Ariz. -- Oncology Drug Development Company Promotes Dr. Evan Hersh to EVP EVP Executive Vice President EVP EGR (Exhaust Gas Recirculation) Valve Position Sensor EVP Electronic Voice Phenomenon EVP Europäische Volkspartei (Germany) EVP Employee Value Proposition and Chief Medical Officer and Names Wayne Morrison Director of Finance and Administration AmpliMed today announced the promotion of Evan Hersh, M.D. to Executive Vice President, Medical Affairs and Chief Medical Officer and the addition of Wayne Morrison as Director of Finance and Administration. As a co-founder of AmpliMed, Dr. Hersh led the rediscovery of Amplimexon(TM) (imexon inj.) as an anticancer drug anticancer drug see antineoplastic. anticancer drug Chemotherapeutic, see there . Amplimexon is now the lead drug candidate in AmpliMed's clinical development portfolio. As Executive Vice President, Dr. Hersh will assume full responsibility for the planning and execution of all AmpliMed's clinical and scientific development programs. Mr. Morrison brings more than two decades of experience in operations, finance and accounting in the healthcare industry to AmpliMed. He most recently served as Chief Financial Officer for two privately-held developmental stage companies and for NextHealth, Inc., a provider of wellness and preventative healthcare services. Earlier, Mr. Morrison served as President for a privately-held healthcare company specializing in weight loss and lifestyle management. "This is an exciting time for AmpliMed as we have just embarked on Phase I/II clinical trials at five research sites to study Amplimexon in the treatment of pancreatic cancer pancreatic cancer Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. , and with Dr. Hersh assuming an expanded role we expect to bring additional new drugs into clinical trials for various cancer patient populations," said Robert Ashley Robert Ashley is a contemporary composer born March 28, 1930 in Ann Arbor, Michigan, best known for his operas and other theatrical works, often working within and across differing disciplines. , Chairman, Chief Executive Officer and President of AmpliMed. "We are also delighted that Wayne has joined AmpliMed at this critical time in our company's development. His experience will be invaluable as we analyze business opportunities and continue to develop and expand our portfolio of anti-cancer therapies." About AmpliMed Corporation AmpliMed Corporation was founded in 1989 with the support of the University of Arizona (body, education) University of Arizona - The University was founded in 1885 as a Land Grant institution with a three-fold mission of teaching, research and public service. Technology Development Corporation and is focused on the clinical development of chemotherapeutic agents This is a list of specific pharmacologic agents that are known to be of use in the treatment of cancer, otherwise known as chemotherapeutic agents. This list is organized by "type" of agent, though the subsections are not necessarily definitive and are subject to revision. for cancer. AmpliMed's strategy is to develop anti-cancer drugs with novel mechanisms of action designed to overcome some of the limitations, such as myelosuppression (suppression of blood cell counts blood cell count, n an estimation of the number and types of circulating blood cells (e.g., red blood cells [erythrocytic series], white blood cells, differential). ), multi-drug resistance (treatment-induced resistance to many cancer drugs) and cardiac toxicity, frequently associated with current cancer therapy. The company's lead product, Amplimexon(TM) (imexon), is undergoing NDA-directed clinical development. Other products in the company's portfolio include Amplizone(TM), which is anticipated to enter the clinic later in 2005, and a portfolio of derivatives of both lead compounds for future development. AmpliMed Corporation is based in Tucson, Arizona Tucson (pronounced /ˈtusɑn/, Spanish: Tucsón [tuk'son] and is on the Web at http://www.amplimed.com. AmpliMed, Amplimexon and Amplizone are United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. trademarks of AmpliMed Corporation. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion